Evidence map›Paper›PMID 39926854›Full record

ArticleJournal of pharmacy & bioallied sciences2024

Liraglutide Effect on Weight and A1C in Patients with Type 2 Diabetes Mellitus: Real-World Data from a Single Tertiary Care Center in Saudi Arabia.

Awadh AlRashidi, Rasha AlArfaj, Abdullah Al Ruqaib, Emad Masuadi, Munirah AlFaraj, Yousef Al-Saleh, Rakan AlEnezi, Moeber M Mahzari, Mohammed Z Aljulifi

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of pharmacy & bioallied sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Awadh AlRashidiMedical Affairs, Prince Mohammed Medical City, Sakaka, Saudi Arabia.
Rasha AlArfajDepartment of Family and Community Medicine, College of Medicine, Qassim University, Kingdom of Saudi Arabia.
Abdullah Al RuqaibDepartment of Family and Community Medicine, King Fahad Hospital of the University, Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia.
Emad MasuadiInstitute of Public Health, College of Medicine, United Arab Emirates University, UAE.
Munirah AlFarajDepartment of Family Medicine and PHC, King Abdulaziz Medical City, Ministry of National Guard Health Affairs, Riyadh, Saudi Arabia.
Yousef Al-SalehDepartment of Medicine, Healthoasis Hospital, Riyadh, Saudi Arabia.
Rakan AlEneziDepartment of Medicine, Ministry of the National Guard-Health Affairs, Riyadh, Saudi Arabia.
Moeber M MahzariKing Abdullah International Medical Research Center (KAIMRC), Riyadh, Saudi Arabia.
Mohammed Z AljulifiDepartment of Family and Community Medicine, College of Medicine, Majmaah University, Majmaah 11952, Saudi Arabia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: This retrospective study aimed to determine the effect of liraglutide on weight and HbA1c levels in patients with type 2 diabetes mellitus (T2DM) in Saudi Arabia. The present investigation was carried out at a medical facility located in the Kingdom of Saudi Arabia. Materials and Methods: A retrospective analysis was conducted on the clinical records of 290 patients who were diagnosed with T2DM and were above 18 years of age. These patients were administered liraglutide for a minimum of 6 months. The dataset comprised various parameters such as the duration of diabetes, duration of liraglutide therapy, weight, and multiple biochemical markers such as HbA1c and low-density lipoprotein cholesterol levels. These parameters were measured both before and after the administration of liraglutide therapy. Results: The primary metrics evaluated in this study were alterations in body weight and levels of glycated hemoglobin (HbA1c). Over the 24-month observational period, significant reductions in body mass index (38.6 kg/m Conclusion: Liraglutide reduced HbA1c levels and weight and affected multiple metabolic markers in patients with T2DM in a real-world setting in Saudi Arabia.

Indexed as

Hemoglobin A1cliraglutideSaudi Arabiatype 2 diabetes mellitusweight

Identifiers

PMID39926854
PMCPMC11805097

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.